je.st
news
Tag: merck
Merck to Present at the UBS Global Healthcare Conference
2015-05-18 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the UBS 2015 Global Healthcare Conference in New York on May 19, 2015 at 10:30 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/webcasts-and-presentations.html. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: present
global
conference
healthcare
Merck vaccines kill two babies in Mexico, injure dozens more
2015-05-15 20:13:40| Biotech - Topix.net
At least two children are dead and several dozen others are in critical condition after terrorists wielding weapons of mass destruction violently assaulted the young innocents living in the Mexican state of Chiapas, according to reports. No, it wasn't dirty bombs planted by jihadists or airplanes hijacked by Osama bin Laden and Al-Qaeda operatives crashing into buildings that were responsible; the Mexican government is the terrorist in this case, and the weapons of mass destruction are routine childhood vaccines.
28.34% Advantage To 5 Dow Highest Yield, Lowest Price, May Dogs With Merck
2015-05-09 19:38:02| IT Services - Topix.net
Top ten Dow Industrial dividend stocks by yield showed 11.21% higher net gain from a $5k investment in the lowest priced five than from the same investment in all ten. Annual dividends estimated by Yahoo.com divided by closing stock prices as of May 6 determined yields.
Tags: with
price
highest
advantage
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
2015-05-07 14:30:00| Merck.com - Product News
Dateline City: BERKELEY, Calif., and KENILWORTH, N.J. Study will Evaluate Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), in Combination with Plexxikons PLX3397 BERKELEY, Calif., and KENILWORTH, N.J. May 7, 2015 Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikons investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. Language: English read more
Tags: study
combination
evaluating
collaborate
Merck deal boosts sales but not income at Bayer
2015-05-01 06:46:18| Biotech - Topix.net
Bayer Group's net income was down, but sales were boosted in the first quarter as a result of the company's acquisition of Merck & Co. Inc. On Thursday, Bayer reported that net income slipped 8.4 percent to 1.3 billion euros, down from 1.4 billion euros in same period a year ago.
Sites : [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] next »